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Abstract
Motor neurons have an extreme polarized morphology and heavily rely on 
efficient cargo transport along axons to maintain their neuronal connections and 
connections with muscles. Axonal transport deficits have been observed in almost 
all model systems of ALS. More and more studies have confirmed the close genetic 
and mechanistic linkage between axonal transport deficits with ALS pathogenesis. 
Moreover, several therapeutic approaches have been developed to target axonal 
transport deficits in ALS and showed promising effects in disease models. In this 
concise chapter, we summarize some major discoveries of axonal transport deficits 
in ALS pathogenesis and some related therapeutic strategies. We propose that 
targeting axonal transport may provide a potential therapeutic avenue for ALS.
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1. Introduction
The unique morphological feature of neuronal cells compared with other cell 
types is their extreme polarity and the incredibly long axons [1]. Although the soma 
size ranges from 5 μm to 100 µm, axons can be up to 1 m long [1]. Axons keep the 
efficient communication between soma and axonal terminals [1]. This axonal com-
munication is especially important to motor neuron as they not only need connec-
tions with each other but also far reach to muscles in order to control proper muscle 
contractions [2]. As for ALS, axonal transport defects are one of the most prevalent 
reported phenotypes from different model systems [2]. In addition, the classical 
“dying-back” hypothesis could explain the sequence of events during motor neuron 
degeneration in ALS [3]. The idea is that motor neurons lose their connection with 
muscle fibers and that the axon retracts back towards the soma, which ultimately 
results in cell death [3]. This theory is supported by the observation that motor 
neuron pathology begins at the terminal part of the axon and proceeds in a “dying-
back” pattern [3]. In addition, the longest and largest neurites with the highest 
metabolic demand seem to be the most susceptible to this “dying-back”  
phenomenon [3].
Mechanistically, axonal transport process relies on three main elements: car-
goes, microtubules, and motor proteins and their adaptors [1]. Axonal transport 
is tracked on microtubules which are polymers of α-tubulin and β-tubulins [1]. 
Microtubules determine the neuronal polarity with “plus” end at the axonal distal 
part and “minus” end at the soma part [1]. This polarity allows the directionality of 
the axonal transport [1]. Kinesin (mainly responsible for anterograde axonal trans-
port, from soma to axonal terminal) and dynein (mainly responsible for retrograde 
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axonal transport, from axonal terminal to soma) are two types of ATP-dependent 
motor proteins responsible for carrying cargoes along the microtubules [1]. Adaptor 
proteins are responsible for the connection between motor proteins and cargoes 
[1]. Axonal transport maintains the efficient supply of cargoes including proteins, 
RNAs, lipids, and organelles from soma to terminals and is responsible to clear or 
recycle some misfolded proteins or aggregates under cell stress [1]. It is known that 
several ALS genes can directly cause axonal transport defects, and axonal transport 
also actively interacts with other major ALS pathological changes. Gene therapies 
and compounds that target axonal transport have shown beneficial effects in ALS 
animal models, and some have already been tested in clinical trials in the context of 
other diseases. Therefore, a better understanding of transport mechanisms and its 
role in the disease will open up a new therapeutic avenue for ALS.
2. Axonal transport defects in ALS pathogenesis
2.1 ALS mutations directly interfere with the axonal transport machinery
With the fact that about 10% of ALS cases are considered as “familial ALS” 
with clear genetic factors involved [4], several ALS gene mutations have been 
shown which could directly interfere with different aspects of the axonal transport 
machinery and eventually cause axonal transport defects.
ALS genes that are directly linked to kinesin- and dynein-mediated axonal 
transport have been uncovered by the discovery of ALS mutations in kinesin family 
member 5A (KIF5A) and dynactin subunit 1 (DCTN1) [5]. As a member of the 
kinesin family, KIF5A is mainly expressed in neuronal cells. In the year 2018, two 
independent large-scale genome-wide association and exome sequencing studies 
have found that mutations in KIF5A cause ALS [5, 6]. Most of the mutations are 
loss-of-function mutations that localized in the C-terminal region of the protein 
where cargoes bind. KIF5A mutations cause altered ATP activity and the dysfunc-
tion of kinesin-1 that eventually interfere with the anterograde transport of cargoes 
along the microtubules [6]. Moreover, for one of the most common ALS-causing 
genes called fused in sarcoma (FUS) it has been reported that its protein product 
functions as DNA-/RNA-binding protein that can bind or regulate mRNAs of 
several other motor proteins including KIF5C, KIF1B, and KIF3A [7], which are 
actively involved in regulating mitochondrial transport in neurons. Dynactin is a 
multi-subunit protein that binds and activates dynein by forming a dynein-dynac-
tin motor complex that conveys cargoes in a retrograde transport [8]. The DCTN1 
gene encodes dynactin subunit 1, which is responsible for binding microtubules and 
motor proteins. Heterozygous missense mutations in the DCTN1 gene have been 
suggested as risk factors for ALS in both sporadic and familial ALS patients [9].
The direct influence from ALS genes to microtubules has been described by 
the tubulin alpha 4a (TUBA4A) gene and spastic paraplegia 11 (SPG11) gene [10]. 
Exome-wide variant burden analysis revealed that mutations in TUBA4A associ-
ate with both sporadic and familial ALS cases [11, 12]. TUBA4A encodes the 
tubulin alpha 4A protein. Tubulins are the basic constituents of microtubules [11]. 
Mutations in TUBA4A destabilize the microtubule network, diminishing its 
re-polymerization capability that eventually disrupts the transport process [11]. 
Mutations in the SPG11 gene are the cause of autosomal recessive juvenile-onset 
ALS. Most of the mutations are loss-of-function mutations [10]. SPG11 encodes a 
protein called spatacsin, which co-localizes with the cytoskeleton in neurons [13]. 
Knockdown of SPG11 in mice showed a decreased acetylation level of α-tubulins 
[13]. With the fact that acetylation of α-tubulin facilitates the stabilization of the 
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microtubules and the binding of motor proteins to the microtubules, silencing 
SPG11 causes axon outgrowth defects and retrograde axonal retraction in corti-
cal neurons of mice [13]. This is in line with the reduced axon plasticity in human 
iPSC-derived neurons from patients carrying SPG11 mutations [13]. These studies 
highlighted the importance of spatacsin in axon maintenance due to insufficient 
transport and cargo trafficking [13].
Except influencing motor proteins and microtubules, ALS genes can also inter-
fere with axonal transport by affecting the cargoes. As the cargoes can participate 
into different mechanisms, the interplay between axonal transport and other ALS 
pathological mechanisms is also linked via cargo-specific transport. Rab proteins 
are a group of small GTPases that belong to the Ras superfamily [14]. Rabs are 
responsible for proper vesicle sorting, fission, docking, fusion, and transporting 
spatially and temporally by switching from an inactive guanosine 5’-diphosphate 
(GDP)-bound state to an active guanosine 5’-triphosphate [14]. Several Rabs have 
been reported to play a crucial role in driving neuronal transport in the central 
nervous system [14]. Mutations in the ALS2 gene cause juvenile-onset ALS. The 
protein product of the ALS2 gene specifically binds to Rab5 and functions as a 
guanine nucleotide exchange factor (GEF) for Rab5. The vacuolar protein sorting 
9 (VPS9) domain of alsin mediates the activation of Rab5 through endosome and 
guanine-nucleotide exchanging reaction [14]. Most of the ALS2 mutations are 
loss-of-function mutations that cause the loss of the VPS9 domain and eventually 
fail in Rab5 activation [14]. Subsequently, Rab5-dependent endosome and AMPA 
receptor trafficking are hampered in neuronal culture [15, 16]. The reduction 
of GluR2-containing AMPA receptors at the synaptic surface in ALS2 knockout 
neurons results in vulnerability to glutamate toxicity [16]. In addition, more than 
20 mutations in the OPTN gene have been described being the causative mutations 
of ALS [17]. Optineurin, the protein product of OPTN, regulates vesicle trafficking 
by forming a complex with myosin VI and Rab8 [17]. Myosins are a superfamily 
of motor proteins that move cargoes along microtubules, while Rab8 is a marker 
of recycling endosomes. The formation of the complex is Optineurin dependent 
[17]. This complex localizes at the Golgi apparatus and in cytoplasmic vesicles. It 
mediates Golgi organization, post-Golgi trafficking, exocytosis, and the basolateral 
delivery of membrane proteins [17]. In line with this, impaired axonal vesicle trans-
port has been observed in a zebrafish model with optineurin loss. Furthermore, 
chromosome 9 open reading frame 72 (C9orf72), the most common genetic cause 
of ALS, is a GEF for Rab8 and is also associated with Rab1 [18, 19]. The knockdown 
of C9orf72 affects cellular trafficking from the cell membrane to Golgi. Overall, 
Rab-related transport processes are a good example of the cargo-induced impaired 
axonal transport in ALS.
2.2  Interplay between axonal transport defects with other ALS pathogenic 
mechanisms
Based on the genetic discoveries of ALS, intensive studies have proposed several 
major pathogenic mechanisms that contribute to motor neuron degeneration in 
ALS. Together with axonal transport defects, other dysfunctional mechanisms 
such as mitochondrial dysfunction, endoplasmic reticulum (ER) stress, neuro-
inflammation, excitotoxicity, and abnormal DNA/RNA metabolism have been 
identified [4]. Although it is still under debate which mechanism plays the vital role 
in initiating the motor neuron degenerative process, axonal transport defects have 
been reported to interplay with other mechanisms involved in disease progression.
With the most polarized morphological structure, motor neurons demand 
high-energy supply to maintain their normal function in controlling muscle 
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contractions [20]. Mitochondria play a pivotal role as the energy supply center 
in cells. Abnormal mitochondrial morphology and function are observed 
in postmortem tissues from ALS patients as well as in different ALS animal 
models [21]. Mitochondrial transport is important to clear the damaged 
mitochondria and maintain sufficient energy supply from the soma side to the 
distal side in motor neurons [21]. In line with this, fast motor neurons that have 
the highest needs of ATP, are more severely affected in ALS compared to slow 
motor neurons [22]. Therefore, the interplay between mitochondria quality control 
and transport is crucial for motor neuron survival. Mitochondrial movement 
along microtubules is controlled by a large complex containing kinesin, dynein, 
mitochondrial Rho (Miro), and milton [23]. Milton is an adaptor protein that 
connects Miro and motor proteins. Miro is a GTPase localized to the outer 
membrane of mitochondria. Miro is regulated by PINK/Parkin, which are genetic 
modifiers of FUS-induced neurodegeneration [24]. Axonal transport defects 
have been observed in ALS patient-derived motor neurons and FUS transgenic 
flies. Decreased expression of either PINK or Parkin is beneficial for reversing 
the locomotive defects and enhancing the survival of FUS transgenic flies [24]. 
In addition, overexpression of FUS also increased the ubiquitination of the Miro1 
protein [24]. We have observed that mitochondria-associated ER membranes 
(MAM) are significantly decreased in motor neurons carrying FUS mutation 
[49]. As Miro1 tends to localize at MAM sites, the decrease of MAM might cause 
mitochondrial axonal transport reduction due to reduced Miro1-linkage [49]. 
Similarly, mitochondrial transport defects have also been reported for other ALS 
genes including vesicle-associated membrane protein-associated protein B/C 
(VAPB) and C9orf72 genes both in primary cultured neurons and transgenic 
flies [25]. ALS mutant VAPB interferes with anterograde mitochondrial axonal 
transport through disrupting Ca2+ homeostasis and affecting the amounts of 
tubulin associated with the Miro1/kinesin-1 complex [25, 26]. The C9orf72 repeat 
expansion can cause a severe disruption of mitochondrial transport but only a 
slight inhibition of vesicle transport. Although the exact mechanisms are not clear 
yet, evidence showed that the toxicity comes from the DPRs translated from the 
hexanucleotide repeats present in C9orf72 [26].
ER stress is a widely observed pathological change in different ALS models 
[27]. The ER is responsible for protein synthesis and quality control. Misfolded 
proteins are one of the earliest finding in models based on SOD1 mutations and 
later on in other ALS subtypes [27]. In normal conditions, the ER can identify the 
misfolded protein and trigger the unfolded protein response (UPR) to clear these 
proteins [27]. While under ER stress, the misfolded proteins will be accumulated 
without a proper UPR process [27]. It has been suggested that the ER stress can 
also cause an axonopathy and an irregular microtubule distribution [28]. This has 
been highlighted by the discovery that mutations in two major genes called PDLA1 
and PDLA3 that code ER chaperons are linked with ALS [28]. The ER chaperones 
or protein disulfide isomerases (PDIs) play a pivotal role in the UPR process [27]. 
Expression of mutant PDIs in motor neurons affects dendrite outgrowth and causes 
motor defects in mice [26, 28].
TDP-43 aggregation has been identified as the most prevalent clinical patho-
logical hallmark of ALS patients. In addition, the coding gene TARDBP is an 
ALS-causing gene. TDP-43 aggregation also widely occurs in other familial as 
well as sporadic ALS patients. Axonal transport defects have been observed in 
different model systems of ALS with TDP-43 aggregation [29, 30]. TDP-43 muta-
tions impair mRNA transport in transgenic Drosophila, primary cultured mouse 
cortical neurons and stem cell-derived motor neurons from ALS patients [29, 30]. 
Impaired anterograde axonal transport of microtubule plus tip proteins has been 
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observed in primary cultured rat cortical neurons [29]. It has been suggested that 
cytoplasmic TDP-43 aggregation impairs the cytoskeletal integrity and results in 
transport deficits [29, 30]. While another study has shown that age-dependent 
organelle transport defects in iPSC-derived motor neurons from ALS patients 
carrying TARDBP mutations is independent from TDP-43 aggregation [31], thus, a 
clear interplay between TDP-43 aggregation and axonal transport still needs to be 
clarified. Recently, we found that arginine-rich dipeptide repeat proteins (DPRs), 
which are the pathological translational products from C9orf72 repeat expansion, 
can cause axonal transport defects in human stem cell-derived motor neurons [32]. 
We found that several components of the axonal transport machinery interact with 
arginine-rich DPRs both in vitro and in vivo. It has been proposed that arginine-
rich DPRs might directly affect axonal transport through an inhibitory interaction 
with the microtubule-based transport machinery [32].
DNA damage has been recently proposed as an early pathological change in ALS 
patients [33]. With the fact that TDP-43 and FUS are DNA-/RNA-binding proteins, 
the mutations in these genes cause insufficient DNA damage repair and result in 
motor neuron degeneration [33]. Both DNA damage and distal axonal transport 
defects have been observed in ALS patients carrying FUS mutations [34, 35]. It has 
been proposed that DNA damage might play a role in axonal transport defects [34]. 
When DNA damage is induced in cultured motor neurons, axonal transport defects 
occur thereafter [34]. In line with this, improving the DNA damage repair process 
by inhibiting poly(ADP-ribose) glycohydrolase (PARG) shows a rescue of axonal 
transport defects [34]. Although the exact underling mechanism is not clear yet, it 
is very likely that DNA damage might induce universal transcriptional changes of 
some genes that produce proteins that are involved in axonal transport.
3. Therapeutic strategies targeting axonal transport in ALS
As summarized above, different molecular mechanisms underlie axonal trans-
port deficits in ALS. Based on these evidences, therapeutic strategies to restore 
axonal transport deficits have started to emerge. Given the complexity of the axonal 
transport machinery and its regulatory mechanisms, multiple approaches have been 
devised to target the system at different levels.
3.1 Restoring the tracks: approaches to modulate microtubule dynamics
Microtubule-stabilizing agents are currently in clinical use as chemotherapeutic 
drugs [36]. Compounds that modulate microtubule stability have shown promising 
results also in the context of neurodegeneration. Epothilone D, for example, has 
shown beneficial effects in several models of Alzheimer’s disease [37, 38]. Because 
of these findings, Epothilone D underwent a clinical phase 1 trial investigation 
in patients with mild Alzheimer’s disease (NCT01492374, NCT01966666) [39]. 
Beneficial effects have been reported also for Parkinson’s disease [40] and heredi-
tary spastic paraplegia (HSP) [41]. Epothilone D was shown to protect the soma 
and distal axon of spinal motor neurons early in the disease course of the SOD1G93A 
model mouse of ALS [42]. However, this was not associated with improved motor 
performance or survival [42]. While another microtubule-stabilizing agent, 
Noscapine, was shown to restore axonal transport, to delay the onset of symptoms 
and to extend the survival of SOD1G93A mice [43].
Pharmacological agents that increase the level of microtubule acetylation 
have been also used to rescue axonal transport deficits. Acetylated microtu-
bules are considered to be stable, long-lived microtubules [44]. Although the 
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mechanisms and functional consequences of microtubule acetylation is not fully 
understood [44], it has been suggested that acetylation of α-tubulin promotes the 
recruitment of molecular motors kinesin-1 and dynein [45, 46], indicating that 
boosting the level of microtubule acetylation might positively affect intracellular 
transport. Strong evidence has shown that inhibition of HDAC6, a major tubulin 
de-acetylating enzyme, stimulates intracellular transport of different cargoes in 
several models [45–50].
HDAC6 belongs to the histone deacetylases (HDACs) family, and, unlike the 
other HDACs, HDAC6 is mainly localized in the cytoplasm where it associates 
with microtubules and with the dynein-dynactin motor complex containing 
p150glued [51]. In line with these observations, HDAC6 has been implicated in the 
regulation of cytoskeletal stability, intracellular transport, and cell motility [51, 52]. 
The beneficial effect of HDAC6 inhibitors has been shown in a broad variety of 
neurodegenerative diseases. For example, the inhibition of HDAC6 by trichostatin 
(TSA) increases microtubule acetylation and rescues axonal transport deficit 
in primary neurons carrying the LRRK2 mutation, which is the most common 
genetic causes of Parkinson’s disease. In addition, in vivo knockdown of HDAC6 
and administration of TSA restore locomotor deficits caused by LRRK2 mutation 
in a Drosophila model [48]. Inhibition of HDAC6 by TSA or Tubastatin A (TubA) 
restores the levels of acetylated α-tubulin and corrects the axonal transport defects 
in a mutant HSPB1-induced Charcot-Marie-Tooth disease (CMT) mouse model 
[47, 53]. TSA also enhances tubulin acetylation and rescues microtubule-based 
transport deficits observed in Huntington’s disease (HD) mutant cells [46]. However, 
despite the increased microtubule acetylation, the loss of HDAC6 did not rescue 
neurodegenerative phenotypes and deficits in motor coordination in a HD mouse 
model [54]. In contrast, genetic deletion of HDAC6 significantly slows disease 
progression and extends survival of the mutant SOD1G93A mouse model of ALS [55]. 
The therapeutic potential of HDAC6 inhibition in ALS has been further investigated 
in FUS iPSC-derived motor neurons [49]. Both TubA and ACY-738 HDAC6 
inhibitors rescue the axonal transport deficit in ALS patient-derived motor neurons. 
This beneficial effect on intracellular transport was further confirmed using HDAC6 
antisense oligonucleotides (ASOs) [49]. Furthermore, HDAC6 inhibition increases 
the acetylation level of α-tubulin in patient-derived motor neurons [49].
Overall, targeting microtubules might represent an interesting therapeutic 
target in ALS. In particular, modulating the acetylation levels of α-tubulin might 
be beneficial in restoring axonal transport deficits observed early in the disease 
course of ALS. HDAC6 inhibitors have shown promising results in the context of 
ALS; however additional studies are required. For instance, it has been shown that 
HDAC6 plays an important role in autophagy by promoting the clearance of protein 
aggregates [56] including mutant SOD1 [57–59]. In this regard, inhibitors of the 
deacetylation function of HDAC6 that leave the other functions unhampered need 
to be further validated in the available ALS disease models as they might represent 
an interesting therapeutic approach.
3.2 Restoring the motors: the role of kinases
Several kinases can directly modulate axonal transport through phosphorylation 
of motors, adapters, and cargoes [60]. Deregulation of axonal transport by protein 
kinases has been associated to ALS; therefore the possibility of targeting protein 
kinases has started to emerge as a novel therapeutic avenue.
An abnormal activation of p38 MAP kinase (MAPK) was reported in mutant 
SOD1 mice [61–63]. It has been shown that active p38 MAPK phosphorylates 
kinesin-1, leading to impaired translocation of kinesin-1 along axonal microtubules 
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and inhibition of fast axonal transport [62]. The p38 MAPK inhibitor, SB203580, 
completely inhibits mutant SOD1-induced apoptosis of motor neurons in vitro [61]. 
In addition, Semapimod, a p38 MAPK inhibitor potentially suitable for clinical 
purposes, protects motor neurons from degeneration in vivo, although it only 
mildly extends the survival of SOD1G93A mice [61]. Importantly, a more recent study 
has shown that p38 MAPK is directly responsible for SOD1G93A-induced axonal 
transport deficits in motor neurons, further strengthening the link between p38 
MAPK and axonal transport [63]. Both genetic and acute pharmacological inhibi-
tions of p38 MAPK rescue axonal transport deficits in motor neurons of SOD1G93A 
mice both in vivo and in vitro [63]. However, long-term treatment with the p38 
MAPKα inhibitor SB239063 (a potentially interesting compound given the ability to 
cross the blood-brain barrier) has shown significant toxic side effects and, probably 
because of that, failed to improve axonal transport and muscle function in SOD1G93A 
mice [63]. Therefore, additional investigation is required to evaluate and optimize 
the long-term effects of this approach.
Overactivation of GSK3β has been found in the brain and spinal cord of 
SOD1G93A mice as well as in spinal cord samples from sporadic ALS patients [64–67]. 
Inhibition of GSK3β was protective in SOD1G93A transgenic mice in some studies 
[67, 68], but these findings were not confirmed in later ones [69, 70]. Therefore, at 
present, the involvement of GSK3β in ALS remains controversial. Aberrant activa-
tion of cyclin-dependent kinase 5 (CDK5) has been reported in the spinal cord of 
mouse models of ALS [71–73]. Hyperactivation of CDK5 mis-regulates transport of 
several cargoes via the Lis1/Ndel1 complex, which directly regulates dynein activity 
[72]. Reduction of CDK5 activity in neurons from SOD1G93A mice by roscovitine 
rescues transport deficits [72]. Similarly, inhibition of CDK5 by overexpression 
of calpastatin improves motor axon survival, delays disease onset, and increases 
survival of SOD1G93A mice [73].
Overall, modulating kinase activation seems to be beneficial for the transport 
defects in ALS; however most of these studies focus on the SOD1G93A mouse model. 
It remains to be determined whether targeting kinases is beneficial also in the 
context of other ALS-causing mutations. In addition, many protein kinases have 
multiple targets and are involved in several cellular processes. Therefore a more 
detailed understanding of kinase signaling pathways is required to effectively 
implement this strategy.
4. Conclusions and perspectives
Axonal transport defects have been strongly linked with ALS pathogenesis. 
Different therapeutic strategies have been tested in ALS disease models, showing 
prospective results. However, a deeper understanding of the pathological mecha-
nisms that are responsible for axonal transport deficit is required to properly target 
axonal transport in ALS. Most of the therapeutic strategies proposed have been 
mainly tested in the SOD1G93A transgenic mice, and it is still unknown whether they 
are beneficial in other familial ALS models. In addition, the use of iPSC-derived 
motor neurons could potentially help to validate whether these compounds might 
also be beneficial for the sporadic ALS cases.
Other cellular mechanisms have been shown to be altered in ALS. Therefore it is 
not easy to clarify whether altered axonal transport causes neuronal degeneration 
or whether neuronal dysfunction, due to other upstream mechanisms, ultimately 
leads to malfunctioning of axonal transport. However, the evidence that axonal 
transport is an early identifiable phenotype in several in vivo models suggests that 
targeting axonal transport needs to be addressed for an effective treatment.
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Relatedly, studies are ongoing to improve the specificity and the ability of drugs 
to cross the blood–brain barrier. The advent of techniques such as gene therapy 
and antisense oligonucleotides might speed up the process of effectively target-
ing axonal transport in patients. The feasibility of gene therapy to ameliorate 
axonal transport deficits has been already successfully shown in ALS mice [58]. In 
addition, ASOs that specifically target HDAC6 have been already tested in iPSC-
derived motor neurons of FUS patients showing positive effects on transport [49]. 
Therefore, these approaches might represent an interesting area for future research 
and might help to identify effective therapeutic strategies.
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